Magle Chemoswed

The extraordinary general meeting resolved to approve the board of directors' resolution on an issue of shares with payment through set-off with deviation from the shareholders' pre-emption rights. The directed share issue by way of set-off entails that the share capital will increase with up to SEK 360,000 through a new share issue of up to 7,200,000 new shares. Right to subscribe for the new shares shall vest in PRS1 ApS. The subscription price amounts to SEK 33.40 per share. The reason for not applying the shareholders’ pre-emption rights is that Magle Group wishes to set-off debts against new shares in accordance with a merger agreement entered into on 28 June 2024 regarding the acquisition of all shares in pK Biotech ApS and its subsidiary pK Chemicals A/S.

Furthermore, the extraordinary general meeting resolved, in accordance with the board of directors' proposal, to adopt instructions for the nomination committee.

For enquiries, please contact:

Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21

About Magle Group

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com.

Vator Securities is Magle Group's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.